We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intuitive Surgical’s (ISRG - Free Report) six-month share-price performance reflects a tug-of-war between sustained demand for robotic-assisted surgery and investor concerns about valuation, competitive threats and the company’s profitability. The latest operating results reinforce the strength of its underlying business, but a substantial litigation settlement has complicated the earnings picture.
The stock has risen 7.8% over the past six months, underperforming the Zacks Medical – Instruments industry’s 28.7% gain. The stock has fared better than the S&P 500 Index’s 2% decline. Over the past six months, ISRG has lagged its industry peers, Medtronic (MDT - Free Report) and Johnson & Johnson (JNJ - Free Report) , which have recorded share price gains of 36.5% and 24.7%, respectively.
The company’s third-quarter 2026 results, released last month, showed revenue growth of 22% year over year and continued expansion across its da Vinci and Ion platforms. However, a $450 million pretax antitrust settlement charge weighed on reported earnings, creating a variance between operating momentum and bottom-line performance.
6-Month Price Performance
Image Source: Zacks Investment Research
What Explains the Stock’s Six-Month Trajectory?
Strong Procedure Growth and da Vinci 5 Adoption
The central positive driver remains the expansion of robotic-assisted surgery. Intuitive Surgical’s third-quarter results showed worldwide procedures across its da Vinci and Ion platforms increasing approximately 15% year over year. Da Vinci procedures grew 14%, while Ion procedures increased 31%.
The results demonstrate that demand is not limited to one product. The da Vinci platform continues to benefit from a growing installed base and higher procedure volumes, while Ion is expanding in robotic-assisted bronchoscopy. These systems also support recurring revenues from instruments, accessories and services, helping Intuitive Surgical monetize utilization after the initial system sale.
The da Vinci 5 rollout provides an additional growth avenue. Intuitive Surgical placed 315 da Vinci 5 systems in the third quarter, compared with 240 in the prior-year period. This suggests that adoption of its latest multiport platform is progressing, potentially supporting system revenues and future recurring sales as hospitals increase utilization.
Sales Estimate
Image Source: Zacks Investment Research
Robust Earnings Growth Partially Offset by Litigation Settlement
The third-quarter results delivered a mixed financial picture. Revenues rose 22% to $3.05 billion, and adjusted earnings per share (EPS) increased to $3.00 from $2.40 a year earlier. However, GAAP EPS fell to $1.49 from $1.95.
The disparity was primarily driven by a $450 million pretax charge related to the settlement of previously disclosed antitrust class-action litigation. The settlement remains subject to court approval. Intuitive Surgical recorded the charge in selling, general and administrative expenses, reducing reported earnings by 99 cents per share after tax.
The growth in adjusted EPS indicates that underlying operating performance remained robust, but the litigation charge highlights a material financial and legal risk. Beyond this settlement, ISRG faces several other pending lawsuits. Potential legal expenses, compliance requirements and settlement-related restrictions could pose additional financial and operational challenges beyond the one-time charge.
EPS Estimate
Image Source: Zacks Investment Research
Recovery From The Summer Lows Sustaining Momentum
ISRG's six-month performance is better understood as a volatile recovery rather than a sustained rally.
ISRG started 2026 with a downtrend. The stock declined during the first seven months of the year but has shown signs of recovery over the past three months. The rebound appears consistent with investors reassessing the balance between near-term risks and the company's long-term growth potential. Strong procedure volumes, higher system placements and continued da Vinci 5 adoption provide fundamental support. Yet the recovery does not, by itself, establish that the earlier valuation concerns have been resolved.
The October earnings release may have reinforced confidence in the operating trajectory, but the subsequent share-price volatility indicates that investors are still weighing robust growth against legal costs and elevated expectations.
Rising Competition
Competitive developments have become more relevant to the stock's outlook. Medtronic’s Hugo robotic-assisted surgery platform and Johnson & Johnson's OTTAVA system are emerging alternatives in soft-tissue surgery. Johnson & Johnson received FDA De Novo authorization for OTTAVA in July 2026, opening another competitive front in a market long dominated by Intuitive Surgical.
The challenge for competitors is that surgical robotics is not simply a hardware market. Hospitals must consider clinical training, operating-room workflows, instrument availability, system reliability and the costs of switching platforms. Intuitive Surgical's large installed base, established surgeon relationships and recurring-revenue ecosystem provide meaningful competitive advantages.
Nevertheless, as rival platforms progress toward broader commercialization, Intuitive Surgical may face greater pressure to demonstrate clinical and economic value to hospitals. Competitive intensity could eventually affect pricing, placement growth or market share, even if the immediate threat to its leadership remains limited.
Premium Valuation Leaves ISRG Vulnerable to Disappointment
Despite the recent recovery, valuation remains an important consideration. The company’s forward 12-month price-to-earnings (P/E) multiple of 37.13 exceeds the industry average of 28.65, reflecting the premium investors assign to its growth prospects. ISRG also trades at a premium to its peers, supported by robust procedure growth and a strong competitive moat. In comparison, Medtronic and Johnson & Johnson trade at forward P/E multiples of 16.49 and 24.04, respectively.
That premium can be supported by durable procedure growth, recurring revenues and the potential for robotic surgery to penetrate additional procedures and geographies. However, a high earnings multiple also makes the stock sensitive to changes in growth expectations.
If procedure growth slows, hospitals defer purchases, competitive pressure increases or legal costs persist, investors could reduce the multiple they are willing to pay. Conversely, sustained procedure growth and successful adoption of newer platforms could help support the valuation.
5-Year P/E F12M Valuation
Image Source: Zacks Investment Research
Conclusion: Is the Recovery Sustainable?
Intuitive Surgical's share-price trajectory over the past six months reflects improving momentum after a difficult period, rather than an uninterrupted rally. The fundamental case remains supported by double-digit procedure growth, expanding da Vinci and Ion installed bases, and rising adoption of da Vinci 5. Third-quarter revenues and adjusted earnings growth further demonstrate the resilience of its business model.
Despite headwinds from the $450 million antitrust settlement charge, intensifying competition and premium valuation, ISRG’s Zacks Rank #2 (Buy) and Growth Score of A suggest that investors may consider adding the stock to their portfolios. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue?
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) six-month share-price performance reflects a tug-of-war between sustained demand for robotic-assisted surgery and investor concerns about valuation, competitive threats and the company’s profitability. The latest operating results reinforce the strength of its underlying business, but a substantial litigation settlement has complicated the earnings picture.
The stock has risen 7.8% over the past six months, underperforming the Zacks Medical – Instruments industry’s 28.7% gain. The stock has fared better than the S&P 500 Index’s 2% decline. Over the past six months, ISRG has lagged its industry peers, Medtronic (MDT - Free Report) and Johnson & Johnson (JNJ - Free Report) , which have recorded share price gains of 36.5% and 24.7%, respectively.
The company’s third-quarter 2026 results, released last month, showed revenue growth of 22% year over year and continued expansion across its da Vinci and Ion platforms. However, a $450 million pretax antitrust settlement charge weighed on reported earnings, creating a variance between operating momentum and bottom-line performance.
6-Month Price Performance
Image Source: Zacks Investment Research
What Explains the Stock’s Six-Month Trajectory?
Strong Procedure Growth and da Vinci 5 Adoption
The central positive driver remains the expansion of robotic-assisted surgery. Intuitive Surgical’s third-quarter results showed worldwide procedures across its da Vinci and Ion platforms increasing approximately 15% year over year. Da Vinci procedures grew 14%, while Ion procedures increased 31%.
The results demonstrate that demand is not limited to one product. The da Vinci platform continues to benefit from a growing installed base and higher procedure volumes, while Ion is expanding in robotic-assisted bronchoscopy. These systems also support recurring revenues from instruments, accessories and services, helping Intuitive Surgical monetize utilization after the initial system sale.
The da Vinci 5 rollout provides an additional growth avenue. Intuitive Surgical placed 315 da Vinci 5 systems in the third quarter, compared with 240 in the prior-year period. This suggests that adoption of its latest multiport platform is progressing, potentially supporting system revenues and future recurring sales as hospitals increase utilization.
Sales Estimate
Image Source: Zacks Investment Research
Robust Earnings Growth Partially Offset by Litigation Settlement
The third-quarter results delivered a mixed financial picture. Revenues rose 22% to $3.05 billion, and adjusted earnings per share (EPS) increased to $3.00 from $2.40 a year earlier. However, GAAP EPS fell to $1.49 from $1.95.
The disparity was primarily driven by a $450 million pretax charge related to the settlement of previously disclosed antitrust class-action litigation. The settlement remains subject to court approval. Intuitive Surgical recorded the charge in selling, general and administrative expenses, reducing reported earnings by 99 cents per share after tax.
The growth in adjusted EPS indicates that underlying operating performance remained robust, but the litigation charge highlights a material financial and legal risk. Beyond this settlement, ISRG faces several other pending lawsuits. Potential legal expenses, compliance requirements and settlement-related restrictions could pose additional financial and operational challenges beyond the one-time charge.
EPS Estimate
Image Source: Zacks Investment Research
Recovery From The Summer Lows Sustaining Momentum
ISRG's six-month performance is better understood as a volatile recovery rather than a sustained rally.
ISRG started 2026 with a downtrend. The stock declined during the first seven months of the year but has shown signs of recovery over the past three months. The rebound appears consistent with investors reassessing the balance between near-term risks and the company's long-term growth potential. Strong procedure volumes, higher system placements and continued da Vinci 5 adoption provide fundamental support. Yet the recovery does not, by itself, establish that the earlier valuation concerns have been resolved.
The October earnings release may have reinforced confidence in the operating trajectory, but the subsequent share-price volatility indicates that investors are still weighing robust growth against legal costs and elevated expectations.
Rising Competition
Competitive developments have become more relevant to the stock's outlook. Medtronic’s Hugo robotic-assisted surgery platform and Johnson & Johnson's OTTAVA system are emerging alternatives in soft-tissue surgery. Johnson & Johnson received FDA De Novo authorization for OTTAVA in July 2026, opening another competitive front in a market long dominated by Intuitive Surgical.
The challenge for competitors is that surgical robotics is not simply a hardware market. Hospitals must consider clinical training, operating-room workflows, instrument availability, system reliability and the costs of switching platforms. Intuitive Surgical's large installed base, established surgeon relationships and recurring-revenue ecosystem provide meaningful competitive advantages.
Nevertheless, as rival platforms progress toward broader commercialization, Intuitive Surgical may face greater pressure to demonstrate clinical and economic value to hospitals. Competitive intensity could eventually affect pricing, placement growth or market share, even if the immediate threat to its leadership remains limited.
Premium Valuation Leaves ISRG Vulnerable to Disappointment
Despite the recent recovery, valuation remains an important consideration. The company’s forward 12-month price-to-earnings (P/E) multiple of 37.13 exceeds the industry average of 28.65, reflecting the premium investors assign to its growth prospects. ISRG also trades at a premium to its peers, supported by robust procedure growth and a strong competitive moat. In comparison, Medtronic and Johnson & Johnson trade at forward P/E multiples of 16.49 and 24.04, respectively.
That premium can be supported by durable procedure growth, recurring revenues and the potential for robotic surgery to penetrate additional procedures and geographies. However, a high earnings multiple also makes the stock sensitive to changes in growth expectations.
If procedure growth slows, hospitals defer purchases, competitive pressure increases or legal costs persist, investors could reduce the multiple they are willing to pay. Conversely, sustained procedure growth and successful adoption of newer platforms could help support the valuation.
5-Year P/E F12M Valuation
Image Source: Zacks Investment Research
Conclusion: Is the Recovery Sustainable?
Intuitive Surgical's share-price trajectory over the past six months reflects improving momentum after a difficult period, rather than an uninterrupted rally. The fundamental case remains supported by double-digit procedure growth, expanding da Vinci and Ion installed bases, and rising adoption of da Vinci 5. Third-quarter revenues and adjusted earnings growth further demonstrate the resilience of its business model.
Despite headwinds from the $450 million antitrust settlement charge, intensifying competition and premium valuation, ISRG’s Zacks Rank #2 (Buy) and Growth Score of A suggest that investors may consider adding the stock to their portfolios. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.